Nirav Shah to Antineoplastic Agents
This is a "connection" page, showing publications Nirav Shah has written about Antineoplastic Agents.
Connection Strength
0.403
-
Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025; 148(2):180-197.
Score: 0.110
-
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 07 06; 389(1):33-44.
Score: 0.103
-
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK?inhibitor in BTK?inhibitor?naive mantle cell lymphoma. Future Oncol. 2022 Nov; 18(36):3961-3969.
Score: 0.098
-
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 09; 103(9):1511-1517.
Score: 0.072
-
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 07 15; 25(14):4264-4270.
Score: 0.019